Increased expression of TFPI in human carotid stenosis. Issue 155 (July 2017)

• Record Type: Journal Article
• Authors: Stavik, Benedicte; Holm, Sverre; Espada, Sandra; Iversen, Nina; Sporsheim, Bjørnar; Bjerkeli, Vigdis; Dahl, Tuva Børresdatter; Sandset, Per Morten; Skjelland, Mona; Espevik, Terje; Skretting, Grethe; Halvorsen, Bente
• Is Part Of: Thrombosis research. Issue 155(2017)
• Page Start: 31
• Page End: 37
• Publication Date: 2017-07
• Subjects: Atherothrombosis -- Tissue factor pathway inhibitor -- Carotid plaque -- Anticoagulation -- Vascular biology; Thrombosis -- Periodicals; 616.135
• DOI: 10.1016/j.thromres.2017.04.024
• Languages: English
• ISSNs: 0049-3848

Abstract

Abstract: Introduction: Tissue factor (TF) pathway inhibitor (TFPI) is the physiological inhibitor of TF induced blood coagulation and two isoforms exists, TFPIα and TFPIβ. In atherosclerotic plaques, TFPI may inhibit TF activity and thrombus formation, which is the main cause of ischemic stroke in carotid artery disease. We aimed to identify the isoforms of TFPI present in human carotid plaques and potential sources of TFPI. Materials and methods: Human atherosclerotic plaques from carotid endarterectomies were used for mRNA and immunohistochemistry analyses. hPBMCs isolated from buffy coats and THP-1 cells were differentiated and polarized into M1 or M2 macrophages, and subsequently cultured with or without cholesterol crystals (CC). mRNA and protein expression were measured with qRT-PCR and ELISA, respectively, and procoagulant activity was assessed using a two-stage chromogenic assay. Results: TFPIα and TFPIβ mRNA levels were significantly increased in carotid plaques, whereas TF levels were unchanged as compared to healthy arteries. Antibodies against total TFPI showed elevated levels compared to antibodies against free TFPIα, both by immunohistochemical and ELISA detection in plaques. The antibody against total TFPI also co-localized with CD68 and the M1 and M2 markers CD80 and CD163, respectively. The TFPI mRNA expression was elevated and the procoagulant activity was decreased in M2 compared to M1 polarized human macrophages. TFPI was present in early foam cell formation and CC treatment increased the TFPI mRNA expression even further in M2 macrophages. Conclusions: Our data indicate that both isoforms of TFPI are present in advanced plaques and that anti-inflammatory M2 macrophages may be a potential source of TFPI. Highlights: mRNA levels of both isoforms of TFPI are elevated in human carotid plaques. Anti-inflammatory M2 macrophages are less procoagulant active than M1 macrophages, due to increased expression of TFPI. Cholesterol crystals induced TFPI expression further in M2 macrophages, but not in M1 macrophages.